AstraZeneca, Pfizer, GlaxoSmithKline: Emerging Markets Earnings Roundup (Part 2 of 2)
This article was originally published in PharmAsia News
Executive Summary
Restructuring and diversification was the theme of third quarter earnings calls, as both American and European Big Pharma companies continued to shift resources into emerging markets. As a recurring feature, PharmAsia News combs through quarterly earnings reports to bring together the earning season's Asia highlights. Part one covered analysis of Eli Lilly, J&J and Novartis.